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Rosetting Plasmodium falciparum-Infected Erythrocytes Bind to
Human Brain Microvascular Endothelial Cells In Vitro, Demonstrating
a Dual Adhesion Phenotype Mediated by Distinct P. falciparum
Erythrocyte Membrane Protein 1 Domains
Yvonne Adams,a Pongsak Kuhnrae,b Matthew K. Higgins,c Ashfaq Ghumra,a J. Alexandra Rowea
Centre for Immunity, Infection and Evolution, Institute of Infection and Immunity, School of Biological Sciences, University of Edinburgh, Edinburgh, United Kingdoma;
Microbiology Department, King Mongkut’s University of Technology Thonburi, Bangkok, Thailandb; Department of Biochemistry, University of Oxford, United Kingdomc
Adhesion interactions between Plasmodium falciparum-infected erythrocytes (IE) and human cells underlie the pathology of
severe malaria. IE cytoadhere to microvascular endothelium or form rosettes with uninfected erythrocytes to survive in vivo by
sequestering IE in the microvasculature and avoiding splenic clearance mechanisms. Both rosetting and cytoadherence are medi-
ated by the parasite-derived IE surface protein family Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1). Ro-
setting and cytoadherence have been widely studied as separate entities; however, the ability of rosetting P. falciparum strains to
cytoadhere has received little attention. Here, we show that IE of the IT/R29 strain expressing a rosette-mediating PfEMP1 vari-
ant (IT4var09) cytoadhere in vitro to a human brain microvascular endothelial cell line (HBEC-5i). Cytoadherence was inhibited
by heparin and by treatment of HBEC-5i with heparinase III, suggesting that the endothelial receptors for IE binding are hepa-
ran sulfate proteoglycans. Antibodies to the N-terminal regions of the IT4var09 PfEMP1 variant (NTS-DBL1 and DBL2 do-
mains) specifically inhibited and reversed cytoadherence down to low concentrations (<10g/ml of total IgG). Surface plasmon
resonance experiments showed that the NTS-DBL and DBL2 domains bind strongly to heparin, with half-maximal binding at
a concentration of0.5M in both cases. Therefore, cytoadherence of IT/R29 IE is distinct from rosetting, which is primarily
mediated by NTS-DBL1 interactions with complement receptor 1. These data show that IT4var09-expressing parasites are ca-
pable of dual interactions with both endothelial cells and uninfected erythrocytes via distinct receptor-ligand interactions.
The malaria parasitePlasmodium falciparum is capable of avoid-ing clearance by the spleen via means of sequestration,
whereby infected erythrocytes (IE) adhere to endothelial cells lin-
ing microvascular blood vessels via various host receptors (re-
viewed in reference 1). The ability to sequester within the host’s
tissues is mediated by members of the highly variable protein fam-
ily Plasmodium falciparum erythrocyte membrane protein 1
(PfEMP1), expressed on the surface of IE (2–4). PfEMP1 variants
are high-molecular-mass (200 to 400 kDa) proteins containing
multiple extracellular domains, characterized as Duffy-binding
like (DBL) and cysteine-rich interdomain regions (CIDR) (5).
Some of these PfEMP1 domains have been shown to mediate spe-
cific adhesive interactions with host receptors, e.g., CIDR do-
mains bind to CD36 (6) while DBL2-C2 from some PfEMP1
variants binds to ICAM-1 (7).
Parasite adhesion interactions are not restricted to the endo-
thelium; IE can bind uninfected erythrocytes to form rosettes (8)
or platelets to form platelet-mediated clumps (9). Rosetting is an
important parasite adhesion phenotype that has been associated
with virulence and severe malaria in multiple studies (10–12).
However, the behavior and localization of rosetting parasites in
vivo is poorly understood. Rosettes are not seen in the peripheral
bloodstream, suggesting that rosetting parasites are sequestered in
the microvasculature. It is unclear whether this is due to direct
binding of rosetting IE to endothelial cells or to binding of roset-
ting parasites to nonrosetting cytoadherent IE (a rosetting IE can
bind to both uninfected and infected red cells). Limited literature
exists regarding the ability of rosetting parasites to undergo direct
adhesion to microvascular endothelial cells. In 2003, Vogt and
colleagues suggested that rosetting parasites of strain FCR3S1.2
bound to the glycosaminoglycan heparan sulfate on endothelial
cells (13). The parasite ligand for binding was suggested to be the
DBL domain of PfEMP1 variant FCRS1.2var1, which mediated a
dual rosetting and endothelial cell binding phenotype (13). How-
ever, direct adhesion of rosetting IE to endothelial cells was not
demonstrated, and recently a different PfEMP1 variant, IT4var60,
has been identified as the rosetting ligand in FCR3S1.2 parasites
(14). The FCR3S1.2var1 gene may instead be transcribed by non-
rosetting parasites within FCR3S1.2, as parasite populations al-
ways contain a mixture of PfEMP1 variants, even when selected
for a single adhesion phenotype, due to spontaneous var gene
switching in vitro. Therefore, the significance of Vogt et al.’s find-
ings in terms of rosetting parasites is unclear. No other studies
have yet been published on rosetting parasite interactions with
microvascular endothelial cells.
Here, a well-characterized P. falciparum rosetting strain, IT/
R29 (15), was investigated for its ability to bind to a human brain
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microvascular endothelial cell line (HBEC-5i) (16). Adhesion to
HBEC-5i was demonstrated, the adhesion-blocking effects of an-
tibodies to specific PfEMP1 domains were examined, and the role
of heparan sulfate as an endothelial cell receptor was investigated.
MATERIALS AND METHODS
Parasite strains. The rosetting laboratory clone IT/R29 (17), derived
from the IT/FCR3 strain, was the main focus of this study. The rosetting
characteristics of this parasite, including identification of the IT4var09
PfEMP1 variant as the parasite rosetting ligand (15, 18), identification of
complement receptor 1 (CR1) as the major uninfected erythrocyte roset-
ting receptor (15, 19), and rosette disruption by sulfated glycoconjugate
compounds (20, 21), have been described previously. Two nonrosetting
parasite strains were used as positive controls for HBEC-5i binding. They
were FCR3-CSA, which was selected for binding to chondroitin sulfate A
(CSA) (22), a molecule that is well expressed on HBEC-5i (23), and HB3-
HBEC, which was selected for adhesion to HBEC-5i and binds to an un-
known endothelial receptor (24). A negative-control parasite strain, IT
unselected (IT/Uns), that is unable to bind to HBEC-5i, was also used.
IT/Uns was derived from clone IT/A4 (17) grown without selection for
20 generations. IT/Uns binds well to CD36 but poorly to other receptors
(25), and it is unable to bind HBEC-5i, as these cells lack CD36.
Parasite culture. Plasmodium falciparum IE were maintained in cul-
ture with O erythrocytes (Scottish National Blood Transfusion Service)
in RPMI 1640 medium (Invitrogen) containing 25 mM sodium bicarbon-
ate, supplemented with 5% pooled human serum (Scottish National
Blood Transfusion Service), 2 mM L-glutamine (Invitrogen), 25 mM
HEPES (Lonza), 20 mM glucose (Sigma), 25 g/ml gentamicin sulfate
(Lonza), and 0.25% Albumax II (Gibco). The pH was adjusted to 7.2 to 7.4
with the addition of NaOH (Sigma), and flasks were kept at 37°C and
gassed with 1% O2–3% CO2–96% N2. Parasite maturity and parasitemia
were assessed by daily thin blood smears stained with 10% Giemsa.
Assessment of RF. The rosette frequency (RF) of IT/R29 parasites was
determined by viewing a wet preparation of 25g/ml ethidium bromide-
stained culture suspension (10 l on a clean microscope slide covered by
a 22- by 22-mm coverslip) using simultaneous white light and fluores-
cence to visualize both infected and uninfected erythrocytes (40 objec-
tive; Leica DM LB2 microscope). A rosette was defined as an IE that binds
two or more uninfected erythrocytes. The RF is the percentage of IE form-
ing rosettes out of 200 IE counted. For all assays, the RF was calculated in
triplicate for a total of 600 cells from three independent wet preparations
per sample either prior to assay (trophozoite start) or during the previous
cycle (ring start), and parasites with an RF of at least 60% were used in all
experiments.
HBEC-5i culture. HBEC-5i is an immortalized cell line (16) that has
recently been used as an in vitro model for the host-parasite interactions
underlying cerebral malaria and sequestration of IE in the human brain
(24–26). HBEC-5i were seeded onto 50 g/ml fibronectin (Millipore)-
treated flasks and cultured in Dulbecco’s modified Eagle medium
(DMEM)-F12 medium (Sigma) supplemented with 10% heat-inactivated
fetal bovine serum (FBS), 2 mM L-glutamine (Invitrogen), 10g/ml gen-
tamicin sulfate, and 5 ml endothelial growth supplement (ScienCell) (16).
For adhesion assays, cells were seeded onto fibronectin-coated 8-well
chamber slides for a minimum of 48 h prior to the assay (24, 25). The
fibronectin-coated chamber slides were either purchased (BD Biosci-
ences) or coated manually with 50 g/ml fibronectin (Millipore) for 10
min at 37°C prior to seeding with HBEC-5i. Parasite and HBEC-5i cul-
tures were checked regularly for mycoplasma contamination (27), and
only mycoplasma-negative cultures were used for experiments.
Adhesion assays. (i) Pigmented trophozoite start. Pigmented tro-
phozoite IE were resuspended at 1% hematocrit and 5% parasitemia in
bicarbonate-free RPMI 1640 (pH 7.2) containing 2 mM L-glutamine and
25 mM HEPES (Lonza) and supplemented with 10% human serum, (In-
vitrogen), 20 mM glucose (Sigma), and 25 g/ml gentamicin sulfate
(Lonza). The IE (500 l per well; 1 cm2) were added to HBEC-5i cell
monolayers (70% confluence) grown in 8-well chamber slides. Cham-
ber slides were then gassed in a humidified incubation chamber for 2 min
with 1% O2–3% CO2–96% N2 and then incubated at 37°C for 1 h with
gentle agitation every 15 min. After 1 h, the chambers were removed per
the manufacturer’s instructions, and washing was carried out by gently
immersing the slides upright in a staining jar with 50 ml prewarmed
(37°C) washing buffer (RPMI 1640 without bicarbonate, pH 7.2) for 30
min. Adherent IE were fixed in 2% glutaraldehyde in phosphate-buffered
saline (PBS) (Sigma) for 1 h before being stained with 5% Giemsa for 15
min. The number of bound IE in 10 fields was counted using a Leica DM
2000 microscope (40magnification) and expressed as the mean number
of bound IE per mm2 for at least three independent experiments.
(ii) Ring-stage start. IE at ring stage were adjusted to 5% parasitemia
and 1% hematocrit in HBEC-5i medium as described above, and 500l of
parasite suspension was added to each well containing adherent mono-
layers of HBEC-5i in 8-well chamber slides. The brain endothelial cells
and IE were coincubated overnight at 37°C in 5% CO2 to allow for opti-
mum growth conditions for the HBEC-5i. Pilot experiments determined
that the parasites showed normal morphology and maturity when grown
under these conditions. The following day, the chambers were carefully
removed and nonadherent IE washed off by inversion into a petri dish
(90-mm diameter) containing 10 ml prewarmed wash buffer (RPMI 1640
without bicarbonate, pH 7.2) for 30 min. This was done by gently placing
the inverted slides onto Eppendorf tube lids, cut from tubes, to suspend
them above the bottom of the petri dish and allow the removal of nonad-
herent cells by gravity. Manual washing of chamber slides in a staining jar
was too vigorous for the adherent IT/R29; therefore, washing by gravity
preserved the bound IE for fixation. Cells were then fixed in 2% glutaral-
dehyde and stained with Giemsa as described above. The number of
bound IE was counted (10 fields with 40 objective) using a Leica DM
2000 microscope and expressed as the mean number of bound IE per mm2
for at least three independent experiments.
Human primary endothelial cell line adhesion assays. Primary hu-
man brain microvascular endothelial cells (HBMEC) and human pulmo-
nary microvascular endothelial cells (HPMEC) were purchased from Sci-
enCell and cultured by following the manufacturer’s instructions. Briefly,
cells were grown in fibronectin-treated flasks at 37°C in 5% CO2 using
endothelial cell medium (ScienCell) supplemented with 2 mM L-glu-
tamine, 5 ml penicillin-streptomycin (100), 5 ml endothelial growth
supplement (100; ScienCell), and 5% heat-inactivated fetal bovine se-
rum (Gibco). For adhesion assays, cells were seeded onto fibronectin-
coated 8-well chamber slides for a minimum of 72 h prior to the assay, as
described above for HBEC-5i. Ring-stage start adhesion assays were car-
ried out as described above, except endothelial cell medium was used
rather than DMEM-F12.
Antibody production. Rabbit polyclonal antibodies against recombi-
nant proteins representing individual domains of the IT4var09 PfEMP1
variant were generated as previously described (18). Total IgG was puri-
fied as described previously (18) and used over a range of concentrations
from 1 to 100 g/ml. It was not possible to express the CIDR	 domain of
IT4var09 as a soluble protein (18); therefore, antibodies to this domain
were not tested.
Immunofluorescence assay (IFA) on fixed cells. A ring-stage adhe-
sion assay was conducted as described above, and after the final gravity
wash, slide chambers were removed per the manufacturer’s instructions.
The slides were fixed in ice-cold acetone-methanol (90:10) and allowed to
return to room temperature for 30 min. Primary incubation was with 50
l/well of IT4var09 anti-NTS-DBL1 and anti-DBL2	 and negative con-
trols (nonimmunized rabbit IgG and antibody to an irrelevant PfEMP1
variant, NTS-DBL1 of TM180var1 [28]). One mg/ml total IgG stock of
each antibody was diluted 1:5,000 in PBS–1% BSA to give a final concen-
tration of 0.2g/ml, and incubation was for 1 h at room temperature in a
humidified box. Cells were washed 3 times with 50 l PBS/well for 5 min
each time, and then the secondary antibody (Alexa Fluor 488 goat-anti-
Rabbit IgG; A-11034; Invitrogen) was added at 1:1,000 dilution in
Adams et al.
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PBS–1% BSA containing 1 g/ml 4,6-diamidino-2-phenylindole (DAPI)
to stain parasite nuclei and incubated for 45 min as described above. A
final wash was conducted (50 l per well for 5 min each wash) before
mounting with 1.25 mg/ml DABCO (1,4-diazabicyclo[2.2.2]octane) in
50% glycerol–50% PBS (29).
Adhesion inhibition assays. For inhibition assays with antibodies,
anti-NTS-DBL1 and anti-DBL2	 were tested at 1, 10, and 100 g/ml,
while anti-DBL3ε, anti-DBL4
, and anti-CIDR2 antibodies were tested
at 100 g/ml only. Immature ring-stage IT/R29 IE (500 l) at 5% para-
sitemia and 1% hematocrit (in HBEC-5i media) were added to fibronec-
tin-coated 8-well chamber slides containing 70% confluent HBEC-5i
with the appropriate concentration of antibody. The chamber slides were
then incubated overnight at 5% CO2 and 37°C to allow for optimum
growth of the HBEC-5i cells and allow adhesion to occur. The following
day, the chambers were carefully removed and nonadherent IE washed off
by gravity and then fixed and stained as described above. The level of
binding was determined by counting the number of bound IE per mm2 as
described above for at least three independent experiments.
Adhesion reversal assays. To measure the ability of the PfEMP1 an-
tibodies and compounds to reverse adhesion, assays were set up with
ring-stage IT/R29 IE (500 l) at 5% parasitemia and 1% hematocrit (in
HBEC-5i media) being added to fibronectin-coated 8-well chamber slides
containing70% confluent HBEC-5i cells. The chamber slides were then
incubated overnight at 5% CO2 and 37°C to allow adhesion to occur. The
following day, anti-NTS-DBL1 and anti-DBL2	 antibodies were tested
at 1, 10, and 100g/ml, while anti-DBL3ε, anti-DBL4
, and anti-CIDR2
antibodies were tested at 100 g/ml only. In addition, a panel of sulfated
glycoconjugates (heparin, heparan sulfate, fucoidan, CSA, CSB, hyal-
uronic acid [all from Sigma], and curdlan sulfate [30]) were also tested at
100g/ml. For all adhesion reversal assays, the medium within the 8-well
chamber slides was removed with a P1000 pipette, taking care not to
disturb the settled cells, and prewarmed HBEC-5i medium containing the
appropriate test compound/antibody was added and slides were then gen-
tly agitated to mix the cells. Once all compounds were added, the chamber
slides were returned to the 5% CO2, 37°C incubator for 1 h. After 1 h, the
chambers were carefully removed and nonadherent IE washed off by grav-
ity wash as described above. Cells were then fixed in 2% glutaraldehyde
and stained with Giemsa as described above. The adherent cells were
counted and expressed as the mean number of IE bound per mm2 for at
least three independent experiments.
Enzymatic treatment of HBEC-5i. To remove heparan sulfate from
the surface of the HBEC-5i, adhesion assays were performed as described
above with ring-stage IT/R29 IE using a protocol similar to that of the
adhesion reversal assay described above, with some modifications. Previ-
ous assays used fibronectin-coated slides; however, heparinase III treat-
ment caused the cells to lift off; therefore, HBEC-5i cells were seeded onto
0.1% gelatin-coated slides (in PBS for 2 h at 37°C), and the assays were
continued as reported above. After the overnight incubation, medium was
carefully removed from the wells of the chamber slide and replaced with
500 l HBEC-5i medium containing either 0.2 IU/ml heparinase III
(Sigma), 0.5 IU/ml chondroitinase ABC (Sigma), or no enzyme (control).
The 8-well chamber slides were then placed in a humidified box, gassed
with 1% O2–3% CO2–96% N2, and incubated at 27°C, the optimum tem-
perature for heparinase III activity, for 2 h. After 2 h, the chambers were
carefully removed and nonadherent IE washed off, as described above, by
gravity wash. Cells were then fixed in 2% glutaraldehyde and stained with
Giemsa as described above. The level of adhesion was determined by
counting the number of bound IE per mm2 as described above for at least
two independent experiments. An additional control for enzymatic treat-
ment was performed by pretreating HB3-HBEC IE (whose adhesion to
HBEC-5i is not heparan sulfate dependent [25]) with either heparinase III
or chondroitinase ABC to exclude nonspecific enzyme effects.
SPR analysis of heparin binding. Proteins were expressed and puri-
fied as described previously (18), before dialysis into 20 mM HEPES, pH
7.5, 150 mM NaCl, 0.005% Tween 20. Biotinylated heparin was prepared
by dissolving porcine intestinal heparin (Sigma) to 5 mg/ml in 20 mM
sodium phosphate, pH 7.4, 150 mM NaCl. One ml of this was incubated
with 25 l of 50 mM biotin-hydrazide (Pierce) and 15 l of 100 mg/ml
1-ethyl-3-(3-dimethylaminopropyl) for 2 h at 25°C. The biotinylated
heparin was then dialyzed overnight into 20 mM sodium phosphate, pH
7.4, 150 mM NaCl.
Measurements were performed on a Biacore 2000 instrument with a
constant flow rate of 30 l/min. Biotinylated heparin (100 l) was in-
jected over flow cell 2 of a streptavidin-coated SA chip (Biacore) before
channels 1 and 2 were equilibrated with 20 mM HEPES, pH 7.5, 150 mM
NaCl, 0.005% Tween 20. IT4var09 PfEMP1 recombinant proteins (18)
were injected over both flow cells, and the level of specific binding was
obtained from a subtraction of the response from channel 2 from that of
channel 1. After each injection, both channels were regenerated with a
30-l injection of 2 M NaCl, restoring the signal to original levels without
damaging the surface.
Data were analyzed using the BIAevaluation software to obtain maxi-
mum response values for saturated curves. These were plotted against the
concentration of protein using Prism 5.01 (GraphPad Software Inc., CA)
and fitted to a single-site binding model, allowing determination of the
concentration that gave a half-maximal response. Errors are the given
values with 95% confidence.
For competition studies, carbohydrates were dissolved in 20 mM
HEPES, pH 7.5, 150 mM NaCl, 0.005% Tween 20 to 1 mg/ml and filtered
through a 0.2-m membrane (Sartorius). These stocks were mixed with
recombinant IT4var09 DBL2	 domain (18) to a final concentration of 1
M and a range of carbohydrate concentrations (1 to 50 g/ml). These
were incubated for a minimum of 30 min before Biacore measurements
were taken as described above.
Adhesion inhibition assays with CR1 mouse MAbs. Mouse mono-
clonal antibodies (MAbs) J3D3 (Immunotech) and J3B11 (15, 19) and an
IgG1 isotype control (Dako) at 1 g/ml and 0.1 g/ml were added to
fibronectin-coated 8-well chamber slides containing 70% confluent
HBEC-5i. Ring-stage IT/R29 IE (500 l/well) at 5% parasitemia and 1%
hematocrit in HBEC-5i media were added, and the chamber slides were
incubated overnight at 37°C with 5% CO2. The following day, the cham-
bers were carefully removed and nonadherent IE washed off by gravity
and then fixed, stained, and counted as described above.
Graphing and statistical analysis. GraphPad Prism v5.0 was used for
production of graphs and statistical analysis. Mean values for binding with
and without antibodies and compounds were compared by one-way anal-
ysis of variance (ANOVA) with Tukey’s post hoc test. P values of 0.05
were taken to be statistically significant.
RESULTS
IT/R29 rosetting IE bind to HBEC-5i when adhesion assays are
started at ring stage. Using standard adhesion assays with mature
pigmented trophozoite IE, the positive-control parasite strains
FCR3-CSA (mean, 217.2 32.4 [SD] IE per mm2; n 4) and HB3-
HBEC (144.213.1 IE per mm2;n4) both bound well to HBEC-5i
cells, as expected (Fig. 1A, white bars). The negative-control parasite
strain IT/Uns, which binds primarily to CD36 (25), a molecule that is
not expressed on HBEC-5i, showed minimal binding (7.0 2.15 IE
per mm2;n4). Under the same conditions, rosetting IT/R29 IE did
not bind to HBEC-5i (12.2 2.29 IE per mm2;n 4) (Fig. 1A, white
bars). This might be because IT/R29, like IT/Uns, is unable to bind to
any receptors on HBEC-5i. Alternatively, it is possible that IT/R29 IE
are able to bind, but the uninfected erythrocytes in rosettes block
access of IE surface molecules to endothelial receptors. To differenti-
ate between these two possibilities, we initially tried using magneti-
cally activated cell sorting (MACS)-purified IT/R29 IE in order to test
their adhesion in the absence of uninfected erythrocytes. However,
immediately after purification we found that the rosetting IE bound
to other IE in the cell suspension to form enormous aggregates of IE
Cytoadherence of P. falciparum Rosetting Parasites
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that were unable to bind to endothelial cells. Similarly, attempts to
disrupt the rosettes prior to adhesion by mechanical means were un-
successful, because the rosettes reformed immediately.
An alternative approach was to start the assay at ring stage,
prior to the expression of surface PfEMP1 and the onset of roset-
ting (31), by coculturing IE and HBEC-5i. We reasoned that this
would allow the IE to come into contact with the HBEC-5i before
rosetting begins and allow any potential adhesion interactions
FIG 1 IT/R29 IE bind to HBEC-5i in ring-stage start assays. (A) Comparison of adhesion to HBEC-5i starting with pigmented trophozoite-stage-infected
erythrocytes (IE) (white bars) or ring-stage IE (black bars) for parasite strains FCR3-CSA, HB3-HBEC, IT/R29, and IT-Uns. For the trophozoite-stage start assay,
P. falciparum mature pigmented trophozoites at 5% parasitemia were incubated with HBEC-5i grown in 8-well chamber slides for 1 h before unbound IE were
removed by gravity wash, fixed with 2% gluteraldehyde, and stained with Giemsa. For ring-stage start assay, IE at 5% parasitemia were coincubated overnight
with HBEC-5i cells. The following day, unbound IE were removed by gravity wash and fixed and stained as described for the trophozoite-stage start assay. IE
adhesion was assessed by microscopic examination of 10 fields (40 objective), and the mean numbers of IE bound and standard errors from four independent
experiments are shown. The nonrosetting parasite strains FCR3-CSA, HB3-HBEC, and IT-Uns showed no difference in adhesion between ring-stage and
pigmented trophozoite-stage start, whereas the rosetting IT/R29 strain showed significantly higher levels of adhesion after ring stage start (***, P  0.005 by
one-way ANOVA with Tukey’s post hoc test). FCR3-CSA (B) and HB3-HBEC (C) adhesion to HBEC-5i show a diffuse scattering of adherent IE (white arrows).
(D) IT/R29 adherent IE occur in clusters (white arrows). (E) Adhesion of IT/R29 IE to primary human pulmonary microvascular endothelial cells (HPMEC) and
primary human brain microvascular endothelial cells (HBMEC) in ring-stage start assays as described for panels A and B. The mean numbers of IE bound and
standard errors from three independent experiments are shown. Binding to HBMEC was significantly lower than that to HBEC-5i (**, P  0.01 by one-way
ANOVA with Tukey’s post hoc test).
Adams et al.
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with HBEC-5i to be seen. Using the HBEC-adherent positive-
control parasites FCR3-CSA and HB3-HBEC, IE cocultured over-
night from ring stage bound to HBEC-5i at levels comparable to
those measured in the standard pigmented trophozoite start assay
(Fig. 1A, black bars) (no significant difference between ring start
and trophozoite start in each case; paired t test). Similarly, with the
negative-control parasite IT/Uns, incubating overnight from ring
stage with HBEC-5i did not significantly change the levels of ad-
hesion seen (Fig. 1A, black bars). However, overnight coincuba-
tion of IT/R29 IE and HBEC-5i cells allowed adhesion of IT/R29
to be detected and quantified (101.8  21.4 IE per mm2; n  4)
(Fig. 1, black bars). This was significantly higher than the adhesion
observed when the assay was started at pigmented trophozoite
stage (P 0.004 by paired t test). While the overall level of binding
of IT/R29 IE was lower than that of FCR3-CSA and HB3-HBEC,
the ability of IT/R29 to bind was consistent and reproducible. The
pattern of binding shown by IT/R29 IE differed from that of the
other two strains. For FCR3-CSA and HB3-HBEC, the bound IE
were evenly dispersed over the lawn of HBEC-5i (Fig. 1B and C,
white arrows). For IT/R29, most HBEC-5i showed no adherent IE;
however, occasional cells displayed a dense, clustered pattern of 10
to 20 adherent IE (Fig. 1D). During washing stages, rosette-like
clusters of cells were seen binding to HBEC-5i; however, after
fixation with glutaraldehyde, the uninfected erythrocytes were
mostly lost, and only IE remained adherent. The disintegration of
IT/R29 rosettes following treatment with glutaraldehyde has been
noted previously (J. A. Rowe, unpublished data).
Adhesion of IT/R29 IE was also tested in ring-stage start assays
with two primary endothelial cell lines, HPMEC and HBMEC.
Binding was seen with both primary cell lines (Fig. 1E), although
binding was significantly lower to HBMEC than to HBEC-5i (P
0.009 by one-way ANOVA with Tukey’s post hoc test). With each
primary cell line, the bound IE occurred in clusters similar to those
seen with HBEC-5i.
Bound IT/R29 IE are recognized by antibodies against
IT4var09 domains. Rosetting IT/R29 IE express the PfEMP1 vari-
ant IT4var09 (Fig. 2A) (18) (called R29var1 in earlier publications
[15]) with the N-terminal domain (NTS-DBL1) of this variant
mediating binding to erythrocytes (15). To determine if the
HBEC-5i-bound IE are indeed expressing IT4var09, the adherent
cells were tested by immunofluorescence assay (IFA) on fixed cells
with IT4var09-specific rabbit polyclonal IgG antibodies. The anti-
IT4var09 NTS-DBL1 antibody showed bright positive staining
of 100% of adherent IE (Fig. 2B, top row), while the negative-
control wells with nonimmunized rabbit IgG (Fig. 2B, middle
row) and antibodies to an irrelevant PfEMP1 (TM180var1 NTS-
DBL1 [28]) (Fig. 2B, bottom row) showed only faint diffuse
background staining of both HBEC-5i cells and IE. Antibodies to
the IT4var09 DBL2	 domain were also tested and gave positive
staining similar to that of the IT4var09 NTS-DBL1 antibodies
(not shown). The IT4var09 PfEMP1 antibodies gave a smoother
fluorescent pattern using fixed cells, as shown here, than the punc-
tate pattern seen previously using live cells (18, 28). It may be that
during the live cell IFA, PfEMP1 molecules become clustered due
to antibody cross-linking. Alternatively, in fixed cells the antibod-
ies may access internal as well as surface PfEMP1, giving a different
staining pattern. The data shown in Fig. 2 indicate that the HBEC-
5i-binding IE are expressing the IT4var09 variant, shown previ-
ously to mediate rosetting (15); therefore, IT4var09-expressing IE
are capable of both rosetting and endothelial cell adhesion.
Although not examined in detail, two other P. falciparum ro-
setting strains, TM284R (expressing the TM284var1 variant
[32]) and IT/PAR (expressing the IT4var60 variant [28]) were
examined in standard and ring-stage start adhesion assays with
HBEC-5i. For TM284R, binding was seen in ring-stage start as-
says only, whereas for the knobless IT/PAR strain, no binding
was seen in either assay.
Antibodies against IT4var09 can inhibit and reverse adhe-
sion to HBEC-5i. To determine whether PfEMP1 is responsible
for IT/R29 IE adhesion to HBEC-5i cells, rabbit polyclonal anti-
bodies against specific domains of the IT4var09 PfEMP1 variant
(Fig. 2A) were tested for their ability to both inhibit and reverse
adhesion. For adhesion inhibition (Fig. 3A), antibodies against
specific domains at 100g/ml of total IgG were added prior to the
FIG 2 Antibodies against the IT4var09 PfEMP1 variant recognize IE bound to
HBEC-5i. (A) Diagram of the IT4var09 PfEMP1 variant expressed by IT/R29
rosetting IE. The extracellular region is composed of multiple Duffy binding-
like (DBL) and cysteine-rich interdomain regions (CIDR). TM, transmem-
brane region; ATS, acidic terminal segment. (B) Immunofluorescence assay
(IFA) of IT/R29 IE adhering to HBEC-5i. Ring-stage IE at 5% parasitemia were
incubated overnight with HBEC-5i in 8-well chamber slides. The following
day the nonadherent IE were washed off and the slides fixed in acetone-meth-
anol prior to immunostaining. Rabbit polyclonal antibodies against the
IT4var09 NTS-DBL1 domain (anti-IT/R29) at 1:5,000 dilution were incu-
bated for 1 h and then washed prior to detection with Alexa Fluor 488 goat
anti-rabbit IgG at 1/1,000 dilution (green). The nuclei of the cells were stained
with 1 g/ml 4,6-diamidino-2-phenylindole (DAPI; blue; large nuclei are
HBEC-5i, small nuclei are IE). Negative controls were IgG from a nonimmu-
nized rabbit (rabbit IgG) and rabbit polyclonal antibodies to the NTS-DBL1
domain of an irrelevant PfEMP1 variant TM180var1 (anti-TM180) tested at
1/5,000 dilution. Slides were viewed with a 100 objective using a Leica DM
LB2 fluorescence microscope, and images were taken at consistent exposure
for all antibodies. Adherent IE staining with the IT4var09 antibodies are shown
by white arrows.
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assay and coincubated with both ring-stage IE and HBEC-5i cells
overnight. Antibodies against all domains were found to inhibit
adhesion to HBEC-5i, while antibodies to an irrelevant PfEMP1
variant from another strain (anti-TM180var1 [28]), added as a
negative control, failed to significantly alter the adhesion of IT/
R29 IE (Fig. 3A).
Antibodies were then tested for their ability to reverse existing
adhesion by adding them after 24 h of IT/R29 and HBEC-5i co-
culture (Fig. 3B). Both anti-NTS-DBL1 and anti-DBL2	 signif-
icantly reversed adhesion compared to the untreated control (P
0.005 by one-way ANOVA with Tukey’s post hoc test), while anti-
bodies against the remaining domains DBL3ε, DBL4
, and
CIDR2 failed to significantly alter adhesion (Fig. 3B). The effects
of the anti-NTS-DBL1 and anti-DBL2	 antibodies were dose
dependent, and antibodies against the NTS-DBL1 domain in-
hibited and reversed adhesion at lower concentrations than the
anti-DBL2	 antibodies (Fig. 3C and D). The IT4var09 antibodies
did not agglutinate the IE under the conditions used in the assays
described above.
Adhesion of IT/R29 IE to HBEC-5i cells is heparan sulfate
dependent. Previous work had suggested that the glycosamino-
glycan heparan sulfate on endothelial cells can act as a receptor for
adhesion of parasite strain FCR3S1.2 (13). Furthermore, previous
experiments on IT/R29 rosetting parasites had demonstrated a
sensitivity to sulfated glycoconjugates, whereby rosettes were suc-
cessfully disrupted by soluble heparin, fucoidan, and curdlan sul-
fate but were not affected by CSA, CSB, or hyaluronic acid (20,
21). Therefore, the role of sulfated glycoconjugates in IT/R29
binding to HBEC-5i was investigated further. A panel of sulfated
glycoconjugates, including heparin, fucoidan, curdlan sulfate,
CSA, CSB, and hyaluronic acid, were tested for their ability to
reverse the adhesion of IT/R29 IE to HBEC-5i. Mirroring the ef-
fect of sulfated glycoconjugates on rosetting, we found that hepa-
rin, fucoidan, and curdlan sulfate all reversed IT/R29 IE binding to
HBEC-5i, whereas CSA, CSB, and hyaluronic acid had no effect on
binding (Fig. 4A).
Having shown that heparin inhibits IT/R29 HBEC-5i binding,
the role of the physiologically relevant endothelial cell heparan
sulfate proteoglycan was investigated (heparin is a highly sulfated
form of heparan sulfate found only in mast cells). The addition of
soluble heparan sulfate significantly reversed binding of IE, simi-
lar to the effect of heparin (Fig. 4B). To further investigate the role
FIG 3 IT4var09 antibodies inhibit and reverse IT/R29 IE adhesion to HBEC-5i. (A) Antibodies against IT4var09 domains at 100 g/ml inhibited adhesion of
IT/R29 IE to HBEC-5i, whereas negative-control antibodies (nonimmunized rabbit IgG and TM180var1 antibodies) did not. (B) Antibodies against IT4var09
domains were tested at 100g/ml to determine their ability to reverse adhesion of IT/R29 IE to HBEC-5i. Only NTS-DBL1 and DBL2	 antibodies were capable
of significantly reversing adhesion. NTS-DBL1 and DBL2	 antibodies showed a dose-dependent effect in both inhibition (C) and reversal (D) experiments.
Data shown are the means and standard errors from three independent experiments in all cases. Statistical significance was determined by one-way ANOVA with
Tukey’s post hoc test. ***, P 0.005.
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heparan sulfates play in mediating adhesion, HBEC-5i cells were
enzymatically treated to selectively cleave the heparan sulfate mol-
ecules from the surface of the cells. This treatment significantly
reversed the adhesion of IT/R29 IE by 84% (Fig. 4B), indicating
that heparan sulfate molecules are required for adhesion of IT/R29
IE to HBEC-5i. Adhesion of IT/R29 to HBEC-5i cells was not
significantly reduced after control treatment with the chondroiti-
nase ABC enzyme, which removes chondroitin sulfates (Fig. 4C).
To rule out the heparinase III enzyme eliciting an effect upon the
parasite and not the HBEC-5i cells, a control parasite line, HB3-
HBEC, selected for adhesion to HBEC-5i cells (24, 25), was pre-
treated with heparinase III or chondroitinase ABC before use in a
standard pigmented trophozoite-stage adhesion assay. Neither
enzyme was capable of significantly reducing adhesion of HB3-
HBEC to HBEC-5i cells (Fig. 4D).
The PfEMP1 variant IT4var09 possesses multiple heparin-
binding domains. The data described above suggest that IT/R29 IE
bind to HBEC-5i through an interaction with heparan sulfates and
show that antibodies to the NTS-DBL1 and DBL2	 domains of the
IT4var09 PfEMP1 reverse adhesion. The antibody reversal data sug-
gest that the NTS-DBL1 and DBL2	 domains of IT4var09 are di-
rectly involved in binding to heparan sulfate. To test this hypothesis,
heparin binding by each of the four DBL domains from the IT4var09
PfEMP1 variant (Fig. 2A) was tested by SPR. While the DBL3ε and
DBL4
 domains showed little or no binding to a heparin-coated sur-
face, both NTS-DBL and DBL2	 bound strongly (Fig. 5A and B).
Equilibrium analysis of saturated responses due to binding of differ-
ent concentrations of NTS-DBL1 and DBL2	 showed half-maxi-
mal binding at a concentration of0.5 M in both cases. Attempts
were also made to fit kinetic data to a variety of binding models, but
the dissociation kinetics were complex and did not fit to a simple 1:1
model, as previously observed for chondroitin sulfate proteoglycan-
binding domains from other PfEMP1 proteins, suggesting the possi-
bility of multiple modes of binding (33).
To further compare the heparin binding of the IT4var09
DBL2	 domain shown by SPR to the adhesion capabilities of IT/
R29 IE, the ability of various sulfated glycoconjugates to block
heparin binding by DBL2	 IT4var09 was assessed (Fig. 5C). The
soluble compounds that block adhesion of IT4var09 DBL2	 to
heparin by SPR (heparin, fucoidan, and curdlan sulfate) mirror
FIG 4 Adhesion of IT/R29 IE to HBEC-5i is heparan sulfate sensitive. (A) The ability of sulfated glycoconjugate compounds to reverse IT/R29 IE adhesion to
HBEC-5i was tested by incubating cocultured IT/R29 IE and HBEC-5i for 1 h with 100 g/ml of compound. Slides were then washed by gravity, fixed with 2%
glutaraldehyde, stained with Giemsa, and assessed by microscopy (10 fields, 40 objective). The sulfated glycoconjugate compounds were dissolved in PBS, and
the negative control was the addition of an equivalent volume of PBS alone with no added compound. (B) The ability of 100g/ml of heparin and heparan sulfate
to reverse IT/R29 IE adhesion was performed as described for panel A. The effect of heparinase III on adhesion reversal was studied by incubation of cells with
0.2 IU/ml of enzyme for 2 h to remove heparan sulfate residues. Cells were washed, stained, and assessed by microscopy as described for panel A. Data shown are
the means and standard errors from at least three independent experiments for panels A and B. (C) Soluble CSA (100 g/ml for 2 h) and chondroitinase ABC
enzyme (0.5 IU/ml for 2 h) were tested for their ability to reverse IT/R29 adhesion as described for panels A and B. (D) Heparinase III (0.2 IU/ml for 2 h) and
chondroitinase ABC (0.5 IU/ml for 2 h) were tested for their effect on HB3-HBC adhesion. For panels C and D, the negative control was addition of an equivalent
volume of PBS alone with no added compound/enzyme, and in each case means and standard errors from 2 independent experiments are shown. Statistical
significance was determined by one-way ANOVA with Tukey’s post hoc test. ***, P 0.005.
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those that also disrupt rosettes (20, 21) and reverse adhesion of
IT/R29 IE to HBEC-5i cells (Fig. 4A), whereas the nonblocking or
poorly blocking compounds (CSA, CSB, CSC, and hyaluronic
acid) have no reversal effect on rosetting (20) or HBEC-5i binding
of IT/R29 IE (Fig. 4A). These data suggest that the heparin binding
of the IT4var09 DBL2	 domain demonstrated by SPR is physio-
logically relevant to the binding capabilities of IT/R29 IE.
CR1 does not play a role in endothelial cytoadherence of IT/
R29 IE. Rosetting of IT/R29 parasites is dependent on CR1 on
uninfected erythrocytes (15, 19). To explore whether CR1 also
could play a role in endothelial cytoadherence, we tested the abil-
ity of a rosette-disrupting CR1 MAb, J3Bll, to inhibit adhesion of
IT/R29 IE to HBEC-5i. J3B11, the control MAb J3D3 (a non-
rosette-disrupting CR1 MAb), and an isotype control failed to
significantly inhibit adhesion of IT/R29 IE to HBEC-5i (Fig. 6),
indicating that CR1 does not play a role in IT/R29 cytoadherence.
These results are consistent with previous data showing that CR1
could not be detected on HBEC-5i or HPMEC (34).
DISCUSSION
Despite the importance of rosetting as a parasite adhesion pheno-
type linked to life-threatening malaria, the ability of rosetting IE to
contribute to P. falciparum sequestration by binding directly to
endothelial cells remains poorly understood. The data presented
here show that IE of the rosetting IT/R29 strain can bind to mi-
crovascular endothelial cells in vitro. Furthermore, we identified
both the host receptor (heparan sulfate) and the parasite ligand
(PfEMP1) and showed that two domains of the IT04var09
PfEMP1 variant (NTS-DBL1 and DBL2	) are involved in bind-
ing interactions. Adhesion of IT/R29 IE was only apparent when
the parasites were cocultured with HBEC-5i from ring stage (be-
fore rosetting begins), probably because at later stages, the pres-
ence of rosettes interferes with interaction of IE with the endothe-
lial cell surface. The pattern of adhesion observed was different
from that seen with other nonrosetting adherent parasite strains,
such as FCR3-CSA (which binds CSA) and HB3-HBEC (which
binds an unknown endothelial cell receptor). For the latter two
strains, IE bind in an even distribution over a lawn of endothelial
cells (Fig. 1B and C), while for IT/R29 binding was clustered, with
a small number of endothelial cells showing dense binding of mul-
tiple IE (Fig. 1D). It is unclear whether the clustered distribution
of IT/R29 IE is due to variation in heparan sulfate expression levels
or sulfation patterns on the HBEC-5i cells or is a “seeding” effect,
whereby one adherent IE attracts others, partly due to their inter-
actions with the HBEC-5i cells and partly due to the rosetting IE
binding other IE.
Previous work has identified the NTS-DBL1 domain of the
IT4var09 PfEMP1 variant as mediating rosetting via interactions
with CR1 on uninfected red cells (15, 19). Interestingly, our results
indicate that this PfEMP1 domain is also capable of mediating
adhesion to endothelial cells, as antibodies directed against it
could both inhibit and reverse adhesion in a dose-dependent
manner (Fig. 3), and direct binding of NTS-DBL1 to heparin was
demonstrated by SPR (Fig. 5). These data strongly suggest this
domain has a dual adhesive phenotype, in that it mediates both
rosetting and cytoadherence. However, rosetting of IT/R29 IE in-
volves CR1 as a receptor, whereas our data indicate that endothe-
lial cytoadherence occurs via heparan sulfate (Fig. 4) and does not
involve CR1 (Fig. 6). IT/R29 rosetting is not thought to involve
heparan sulfate-like molecules on erythrocytes, because treatment
of erythrocytes with heparinase enzyme does not reduce IT/R29
rosetting (35). Therefore, our data suggest that distinct PfEMP1
domains within a single variant can interact with different recep-
tors to bring about adhesion to alternative human cell types. It
remains possible that interactions with heparan sulfate-like mol-
ecules on erythrocytes contribute to strengthening IT/R29 ro-
settes, even if they are not essential for rosette formation.
Our investigations also identified a second PfEMP1 domain
involved in cytoadherence, the DBL2	 domain. In contrast to
NTS-DBL1, antibodies raised against DBL2	 of IT4var09 did
not inhibit or reverse rosetting (18) but did successfully inhibit
and reverse adhesion to HBEC-5i cells (Fig. 3). These data suggest
that the DBL2	 domain is involved in mediating endothelial ad-
hesion but does not play a major role in rosetting. It is possible that
the DBL2	 antibody can reverse cytoadhesion but not rosetting,
because the binding of IE to endothelial cells is weaker than the
binding to uninfected erythrocytes in rosettes.
FIG 6 Adhesion of IT/R29 IE to HBEC-5i is not CR1 dependent. Mouse
monoclonal antibodies to CR1 were tested for their ability to inhibit adhesion
of IT/R29 IE to HBEC-5i, and no significant inhibition was seen. Data shown
are the means and standard errors from two independent experiments.
FIG 5 IT4var09 NTS-DBL1 and DBL2	 domains bind heparin, and the
binding is inhibited by sulfated glycoconjugates. (A) SPR signal for the binding
of IT4var09 NTS-DBL1 from a maximum concentration of 4 M to a hepa-
rin-coated surface. (B) SPR signal for the binding of DBL2	 from a maximum
concentration of 4 M to a heparin-coated surface. (C) Competition experi-
ments in which the IT4var09 DBL2	 domain was incubated with different
concentrations of glycoconjugates before assessment of binding to a heparin-
coated surface.
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It has been suggested previously that demonstration of binding
of individual PfEMP1 domains to sulfated glycoconjugate mole-
cules in vitro was not necessarily predictive of meaningful interac-
tions between native full-length PfEMP1 on the surface of IE and
sulfated glycoconjugates (36). In our study, the results from sin-
gle-domain SPR experiments showed that IT4var09 NTS-DBL1
and DBL2	 domains bind heparin, and that the interaction is
inhibited by soluble heparin, fucoidan, and curdlan sulfate but not
by CSA, CSB, CSC, or hyaluronic acid. These results exactly mir-
ror the effect of sulfated glycoconjugates on IT/R29 rosette disrup-
tion (20) and IT/R29 binding to HBEC-5i (Fig. 4A), giving confi-
dence that in this case, the results of SPR with individual domains
are biologically meaningful. Given the distinct receptors involved
in IE cytoadherence to HBEC-5i and rosetting, it seems likely that
the cytoadherence-blocking effect of heparin and other sulfated
glycoconjugates (Fig. 4) is due to direct blockade of the receptor-
ligand interaction, whereas the rosette-inhibiting effects of these
compounds (20, 21) may occur due to steric or electrostatic ef-
fects, as suggested previously (37).
Our initial studies on rosetting IE interactions with endothelial
cells using standard assays with pigmented trophozoite-stage par-
asites were unsuccessful (Fig. 1), most likely due to the presence of
rosettes blocking interactions between IE surface molecules and
endothelial cell receptors. The inhibitory effect of preexisting
rosettes on adhesion is supported by previous work of Handun-
netti and colleagues, who used the CD36-dependent rosetting lab-
oratory parasite strain Malayan Camp and showed that IE could
bind to purified CD36 protein or C32 melanoma cells but only
adhered well if rosettes were disrupted prior to the assay (38).
However, most P. falciparum rosetting isolates are not CD36 de-
pendent (19, 39, 40), so the broader significance of the findings
reported with the Malayan Camp strain are unclear. The possibil-
ity of adhesion of rosetting IE to endothelial cells was also sug-
gested by Udomsangpetch et al., who demonstrated binding to
HUVEC via an unknown receptor (41). However, HUVECs show
many differences in receptor expression and biological functions
compared to microvascular endothelial cells (42), and the signif-
icance of these findings in terms of microvascular adhesion was
unclear. The more recent work by Vogt and colleagues (13) did
use a microvascular human lung endothelial cell line as well as
HUVEC, but as outlined in the introduction, it is likely that non-
rosettting IE were studied. Therefore, our report represents the
first clear demonstration, to our knowledge, that rosetting IE can
bind directly to microvascular endothelial cells.
Further experiments will be necessary to test the physiological
significance of the IE-endothelial cell interactions described here.
The interactions between IT/R29 IE and endothelial cells were
relatively weak, as gentle gravity washes were required to visualize
the binding. We did attempt to study IT/R29 IE interactions with
HBEC-5i under flow conditions and saw rolling of rosetting IE
with a low level of adhesion (3 to 4 per field of 200 m2; data not
shown) at shear stresses similar to those found in the microvascu-
lature in vivo (0.5 to 1.0 dyn/cm2) (43). However, as described
above for the static assays, the flow experiments are complicated
by the presence of rosettes potentially blocking interaction be-
tween IE surface molecules and endothelial cells, especially as large
“multirosettes” form under flow conditions (44). Previous exper-
iments using rosetting parasites in an ex vivo model suggested that
rosettes are disrupted in the arterial side of the circulation (due to
high shear forces) but then would reform in the venous side of the
circulation, with rosetting and endothelial cytoadherence occur-
ring simultaneously in postcapillary venules (45). The variation in
vessel size and shear stresses experienced under pulsatile blood
flow in vivo is difficult to mimic in vitro, and further ex vivo exper-
iments may be required to explore more fully the potential of
rosetting parasites to contribute to sequestration via direct cy-
toadherence to endothelial cells. It may be that rosetting IE-endo-
thelial cell interactions are not a major primary cause of seques-
tration in vivo, but that such interactions could contribute to
cytoadherence in areas of low or stagnant flow secondary to se-
questration of nonrosetting IE. Another possibility is that roset-
ting IE make a major contribution to sequestration in vivo via
adhesion to other nonrosetting IE that are bound to endothelial
cells. Our attempt to use MACS-purified IE in adhesion assays was
unsuccessful because of the massive aggregates of IE that rapidly
occur when uninfected erythrocytes are removed from the culture
due to strong binding of rosetting IE to other IE. Clinical isolates
are usually multiclonal, and even within a single clone, multiple
different var genes are expressed, giving a parasite population with
diverse binding characteristics. It may be that in vivo, rosetting can
contribute to sequestration both via direct binding of rosetting IE
to microvascular endothelium in areas of stagnant flow and also
more widely via binding of rosetting IE to cytoadherent nonroset-
ting IE.
Although the precise way in which rosetting contributes to
sequestration is unknown, it remains clear that rosetting is a par-
asite phenotype linked to pathogenicity. Evidence includes the
consistent association between parasite rosette frequency and dis-
ease severity in sub-Saharan Africa (10–12), the virulence of ro-
setting parasites in an animal model (46), and the proven ability of
human erythrocyte polymorphisms that reduce the ability of P.
falciparum to form rosettes to confer significant protection against
life-threatening malaria (47, 48). The work done here emphasizes
the potential for rosette-disrupting interventions that could be
used as adjunctive therapies against severe malaria. Furthermore,
the findings that the same set of sulfated glycoconjugate com-
pounds successfully reverses both rosetting and adhesion to
HBEC-5i cells (Fig. 4) and that antibodies to the NTS-DBL1
domain of IT4var09 reverse both rosetting and adhesion to
HBEC-5i cells (Fig. 3) suggest that it will be possible to identify
therapeutic agents that will disrupt both rosetting and endothelial
adhesion. A heparin derivative lacking anticoagulant effects (49) is
currently undergoing clinical trials, and the data presented here
support the potential of such compounds as adjunctive therapies
for severe malaria.
Taken together, the data shown here illustrate the importance
of the N terminus of the PfEMP1 molecule in adhesion of IT/R29
IE to endothelial cells, as well as rosetting as shown previously, and
support the identification of heparan sulfate as the host endothe-
lial cell receptor. This demonstration of the dual adhesion of
rosette-capable IE to endothelial cells further enhances the argu-
ment for the role of rosetting in severe malaria and pathogenicity.
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